AstraZeneca and Sanofi carry out innovative compound swap

20 November 2015

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and French pharma company Sanofi (Euronext: SAN) are to carry out a direct exchange of 210,000 compounds from their respective proprietary compound libraries.

This exchange represents a novel open innovation model between pharma companies and aims to diversify and broaden the base from which companies carry out the search for new small molecules.

The compounds were selected based on differences from those in the companies’ respective libraries. Chemical structures and synthetic procedures will also be shared to allow the use of these compounds. They will be exchanged in sufficient quantities to enable the receiving company to carry out high-throughput screening for several years to determine whether they are active against specific biological targets. Should a compound match a target, it will go through several modifications to optimize its structure before being classified as a lead compound for development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK